Business Insider19d
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Dupixent ® (dupilumab) confirmatory Phase 3 trial (LIBERTY-CUPID Study C) met the ...
FierceBiotech4d
Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
Business Insider19d
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met ...
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
KTLA19d
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
With a nearly 50% reduction in itch and urticaria activity scores compared to placebo, these positive phase 3 results reaffirm the potential of Dupixent to bring relief and its well-established ...
Enid News & Eagle19d
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for ...
11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Dupixent® (dupilumab) confirmatory Phase 3 trial (LIBERTY-CUPID Study C) met the ...